Source: Annual Congress 2011 - Airway smooth muscle cells and fibroblasts: cell biology
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Oldenburger, S. Roscioni, E. Jansen, M. Menzen, A. Halayko, W. Timens, H. Meurs, H. Maarsingh, M. Schmidt (Groningen, Netherlands; Winnipeg, Canada). LSC 2011 Abstract: Potential anti-inflammatory role of the cAMP effectors Epac and PKA in COPD. Eur Respir J 2011; 38: Suppl. 55, 755

Member's Comments

No comment yet.

Related content which might interest you: Decreased Wnt/β-catenin signaling in COPD: Possible involvement of Wnt antagonists Source: Annual Congress 2012 - New mechanisms in non-neoplastic and neoplastic lung diseases Year: 2012 Phosphoinositide 3-kinase ? inhibitor suppresses interleukin-17 expression in a murine asthma model Source: Eur Respir J 2010; 36: 1448-1459 Year: 2010 The effect of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild to moderate asthma Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Egr-1 regulates muc5ac expression through activator protein-1 (AP-1) in chronic airway inflammation diseases Source: International Congress 2015 – Translational studies in airway cell biology Year: 2015 Late Breaking Abstract - CRAC channel inhibition by RP3128 triggers potent anti-inflammatory effects in COPD or asthmatic patient-derived primary cells Source: International Congress 2018 – New pharmacological strategies in airway diseases Year: 2018 Maintenance of IRF1 by MAPK inhibition: A mechanism by which DUSP1 reduces glucocorticoid inhibition of CXCL10 Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 Decreased PTEN amplifies PI3K signaling and enhances pro-inflammatory cytokine release in COPD Source: International Congress 2016 – Studies in airway cell biology Year: 2016 Activation of IL-32 pathway in COPD Source: Annual Congress 2008 - Cell biology of asthma and COPD Year: 2008 LSC 2010 Abstract: Bacterial-induced protection against asthma through a novel multi-component immunoregulatory mechanism Source: Annual Congress 2010 - Immune modulation of airways diseases Year: 2010 Role of the kinase-dependent functions of RIPK1 in COPD Source: Virtual Congress 2020 – Physiological and cellular mechanisms affecting pulmonary pathologies Year: 2020 Impaired MAP kinase-dependent modulation of transcription factor T-bet in T-lymphocytes from asthmatics - role of dexamethasone Source: Eur Respir J 2005; 26: Suppl. 49, 233s Year: 2005 The effect of a novel phosphoinositide 3-kinase Δ inhibitor (PI3KΔ), GSK2269557, on potential biomarkers measured from the lungs of healthy male smokers Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018 Inhibition of p38 mitogen-activated protein kinase has no effect on macrophage phagocytosis of bacteria in patients with COPD Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection Year: 2013 Inhibition of phosphodiesterase 4B enhances glucocorticoid-dependent gene transcription in human airway epithelial cells: Implications for the treatment of COPD Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 LSC 2010 Abstract: Genetic or pharmacologic inhibition of ATX stimulates LPS-induced pulmonary inflammation Source: Annual Congress 2010 - Acute lung injury: barrier properties and leukocyte activation Year: 2010 LSC 2011 Abstract: Suppression of antitumor immunity as a potential link between inflammation and cancer in COPD Source: Annual Congress 2011 - COPD: human studies Year: 2011 NLRP3 inflammasome is activated via phosphoinositide 3-kinase δ pathway in Aspergillus fumigatus-induced allergic airway inflammation Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015 In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Activation of second messenger pathways in alveolar macrophages by endotoxin Source: Eur Respir J 2002; 20: 210-222 Year: 2002